{"paper_id":"47fe0131-3f4f-4732-98a3-d41bc029dc56","body_text":"Current Diagnosis & Management of Endometriosis with high risk of Cardiovascular Diseases\nMain Article Content\nAbstract\nIntroduction: Endometriosis is an enigma when it comes to the theories. It is a chronic gynaecological condition which leads to chronic pelvic pain with heavy menstrual bleed for the patient. Even though it is primarily a gynaecological condition, it has shown to have a connection with cardiovascular health especially due to oxidative stress and chronic inflammation. There has been a decline in cardiovascular health either due to disease process or due to the side effects of the treatment for endometriosis.\nMethods: There are studies which showed a direct pathophysiological association between cardiac health and endometriosis due to oxidative stress induced damage to endothelial cells, compromised vascular functions and accelerated atherosclerosis. Molecular pathways demonstrate markers which points towards a decline of cardiac health.\nResult: The impact of treatment of endometriosis has its own impact on the cardiovascular system especially when it is either due to combined oral contraceptives, COX-2 inhibitors or even definitive surgeries in younger patients.\nConclusion: Endometriosis and cardiovascular health are intertwined by its shared pathophysiology and management strategies. It is of paramount importance that the overall health is kept in mind while diagnosing and treating endometriosis. Early diagnosis and strategic treatment that are safe for cardiac health for predisposed women are to be considered. A focus on the current development of safer management strategies can be adopted for a more holistic approach to both cardiac and reproductive health.\nDownloads\nArticle Details\nSection\nThis work is licensed under a Creative Commons Attribution 4.0 International License.\nAuthors retain copyright and grant the Archives of Dental and Medical Sciences the right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share, copy, distribute, and adapt the work, provided the original authors and source are credited.\nAuthors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.\nHow to Cite\nReferences\nZhang J, Pang M, Li L, Guo C. Global, regional, and national burden of endometriosis among women of reproductive age, 1990-2021: insights from the Global Burden of Disease Study 2021. PLoS One. 2025;20(11):e0337074.\nParasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34-41.\nCano-Herrera G, Salmun Nehmad S, Ruiz de Chávez Gascón J, Méndez Vionet A, van Tienhoven XA, Osorio Martínez MF, et al. Endometriosis: a comprehensive analysis of the pathophysiology, treatment, and nutritional aspects, and its repercussions on the quality of life of patients. Biomedicines. 2024;12(7):1476.\nWorld Health Organization. Cardiovascular diseases (CVDs) [Internet]. World Health Organization. 2025 [cited 2026 Oct 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)\nLopez EO, Jan A. Cardiovascular disease [Internet]. National Library of Medicine. StatPearls Publishing; 2023 [cited 2026 Oct 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535419/\nGarcia M, Mulvagh SL, Bairey Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118(8):1273-1293.\nCirillo M, Argento FR, Attanasio M, Becatti M, Ladisa I, Fiorillo C, et al. Atherosclerosis and endometriosis: the role of diet and oxidative stress in a gender-specific disorder. Biomedicines. 2023;11(2):450.\nMelo AS, Rosa-e-Silva JC, Rosa-e-Silva ACJ de S, Poli-Neto OB, Ferriani RA, Vieira CS. Unfavorable lipid profile in women with endometriosis. Fertility and Sterility. 2010 May;93(7):2433–6.\nLamceva J, Uljanovs R, Strumfa I. The main theories on the pathogenesis of endometriosis. Int J Mol Sci. 2023;24(5):4254.\nBarbieri RL. Stenosis of the external cervical OS: An association with endometriosis in women with chronic pelvic pain. Fertility and Sterility. 1998 Sept;70(3):571–3.\nD'Hooghe TM, Debrock S. Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons. Hum Reprod Update. 2002;8(1):84-88.\nJungheim ES, Allsworth JE, Jimenez PT, Schon SB, Doblado MA. Early menstrual characteristics and endometriosis: Treloar et al. American Journal of Obstetrics and Gynecology. 2010 June;202(6):660–1.\nNnoaham KE, Webster P, Kumbang J, Kennedy SH, Zondervan KT. Is early age at menarche a risk factor for endometriosis? A systematic review and meta-analysis of case-control studies. Fertil Steril. 2012;98(3):702-712.e6.\nWei M, Cheng Y, Bu H, Zhao Y, Zhao W. Length of menstrual cycle and risk of endometriosis: a meta-analysis of 11 case-control studies. Medicine. 2016;95(9):e2922.\nMarsh EE, Laufer MR. Endometriosis in premenarcheal girls who do not have an associated obstructive anomaly. Fertil Steril. 2005;83(3):758-760.\nS Sasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. Ann N Y Acad Sci. 2008;1127:106-115.\nParag DJ, Vijayanand KM, Lakshmi K. Gastrointestinal deep infiltrative endometriosis with lymph node involvement. Indian Journal of Pathology and Microbiology. 2021 Jan;64(1):213–5.\nDjokovic D, Calhaz-Jorge C. Somatic stem cells and their dysfunction in endometriosis. Front Surg. 2015;1:51.\nHong IS. Endometrial stem/progenitor cells: Properties, origins, and functions. Genes & Diseases [Internet]. 2023 May 1 [cited 2026 Oct 28];10(3):931–47. Available from: https://www.sciencedirect.com/science/article/pii/S2352304222002306\nWang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14(2):135.\nMaruyama T. A revised stem cell theory for the pathogenesis of endometriosis. J Pers Med. 2022;12(2):216.\nSignorile PG, Viceconte R, Baldi A. New insights in pathogenesis of endometriosis. Front Med. 2022;9:879015.\nKonrad L, Dietze R, Kudipudi PK, Horné F, Meinhold-Heerlein I. Endometriosis in MRKH cases as a proof for the coelomic metaplasia hypothesis? Reproduction. 2019;158(2):R41-R47.\nCharatsi D, Koukoura O, Ntavela IG, Chintziou F, Gkorila G, Tsagkoulis M, et al. Gastrointestinal and urinary tract endometriosis: a review on the commonest locations of extrapelvic endometriosis. Adv Med. 2018;2018:3461209.\nNezhat C, Lindheim SR, Backhus L, Vu M, Vang N, Nezhat A, et al. Thoracic endometriosis syndrome: a review of diagnosis and management. JSLS. 2019;23(3):e2019.00029.\nSzpila G, Szczotka J, Suchodolski A, Szulik M. Endometriosis and cardiovascular disease: exploring pathophysiological interconnections and risk mechanisms. Diagnostics. 2025;15(12):1458.\nMarchandot B, Curtiaud A, Matsushita K, Trimaille A, Host A, Faller E, et al. Endometriosis and cardiovascular disease. Eur Heart J Open. 2022;2(1):oeac001.\nMartins AF, Neto AC, Rodrigues AR, Oliveira SM, Sousa-Mendes C, Leite-Moreira A, et al. Metformin prevents endothelial dysfunction in endometriosis through downregulation of ET-1 and upregulation of eNOS. Biomedicines. 2022;10(11):2782.\nPabon MA, Wang X, Rexrode KM. Beyond reproductive health: The cardiovascular risks of endometriosis. European Heart Journal [Internet]. 2024 Sept 24 [cited 2026 Oct 28];. Available from: https://doi.org/10.1093/eurheartj/ehae674\nTani A, Yamamoto S, Maegawa M, Kunimi K, Matsui S, Keyama K, et al. Arterial stiffness is increased in young women with endometriosis. J Obstet Gynaecol. 2015;35(7):711-715.\nWellbery C. Diagnosis and treatment of endometriosis. American Family Physician [Internet]. 1999 Oct 15 [cited 2026 Oct 28];60(6):1753–62. Available from: https://www.aafp.org/afp/1999/1015/p1753\nZanelotti A, Decherney AH. Surgery and endometriosis. Clin Obstet Gynecol. 2017;60(3):477-484.\nMu F, Rich-Edwards J, Rimm EB, Spiegelman D, Missmer SA. Endometriosis and risk of coronary heart disease. Circ Cardiovasc Qual Outcomes. 2016;9(3):257-264.\nKaminski P, Szpotanska-Sikorska M, Wielgos M. Cardiovascular risk and the use of oral contraceptives. Neuro Endocrinol Lett. 2013;34:101-105.\nPatrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol. 2016;82(4):957-964.\nIkdahl E, Kerola A, Sollerud E, Semb AG. Cardiovascular implications of non-steroidal anti-inflammatory drugs: a comprehensive review, with emphasis on patients with rheumatoid arthritis. Eur Cardiol. 2024;19:e27.\nRoach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;2015(8):CD011054.\nMueck AO. Progestin effects in endometriosis treatment: New research on mechanisms. hmbci. 2010 Dec 1;3(3):469–72.\nFerreira RA, Vieira CS, Rosa-e-Silva JC, Rosa-e ACJS, Nogueira AA, Ferriani RA. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception. 2010;81(2):117-122.\nNew EP, Mikhail E. A narrative review of using GnRH analogues to reduce endometriosis recurrence after surgery: a double-edged sword. Gynecol Pelvic Med. 2021;4:8.\nLim MW, Lucas-Herald AK, Mason A, Delles C, Connelly PJ. Sex differences in the cardiovascular effects of GnRH analogues. J Endocrinol. 2024;261(1).\nTaylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28-40.\nPiróg M, Kacalska-Janssen O, Jach R, Ząbczyk M, Natorska J. Fibrin clot properties among women with endometriosis and the impact of ovarian stimulation. Reproductive BioMedicine Online [Internet]. 2021 Mar 16 [cited 2026 Oct 28];43(1):81–90. Available from: https://www.sciencedirect.com/science/article/pii/S1472648321001097.\nZąbczyk M, Ariëns RA, Undas A. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice. Cardiovasc Res. 2023;119(1):94-111.\nPritchard KI, Abramson BL. Cardiovascular health and aromatase inhibitors. Drugs. 2006;66(13):1727–40.\nBuggio L, Dridi D, Barbara G, Merli CEM, Cetera GE, Vercellini P. Novel pharmacological therapies for the treatment of endometriosis. Expert Review of Clinical Pharmacology. 2022 Aug 30;15(9):1039–52.\nSitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21(13):865-883.\nDonnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020;114(1):44-55.","source_license":"CC0","license_restricted":false}